AstraZeneca has sold the US rights to its Crohn’s disease therapy Entocort to Perrigo as part of its strategy to divest products out of its core therapeutic areas.
Under the terms of the agreement, Perrigo will pay AstraZeneca $380 million for the rights to sell Entocort (budesonide) and its authorised generic Entocort marketed by Par Pharmaceuticals. US product sales of Entocort were $89 million in the first nine months of 2015.
Luke Miels, head of global product and portfolio strategy at AstraZeneca, said the deal highlights “our strategic focus on three main therapy areas and providing further simplification of our supply chain”. Those three areas are respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as infection and neuroscience diseases.
Perrigo CEO Joseph Papa said the addition of Entocort “represents a strong strategic fit with our portfolio of prescription medicines. It supports our commitment to providing effective, affordable treatments to patients with gastroenterological conditions and we look forward to building on the brand’s success in the US market”.
In July, AstraZeneca sold the non-US rights to Entocort to Germany’s Tillotts Pharma.